234 related articles for article (PubMed ID: 32045365)
1. Adaptive selection in the evolution of programmed cell death-1 and its ligands in vertebrates.
Ahmad HI; Zhou J; Ahmad MJ; Afzal G; Jiang H; Zhang X; Elokil AA; Khan MA; Li L; Li H; Ping L; Chen J
Aging (Albany NY); 2020 Feb; 12(4):3516-3557. PubMed ID: 32045365
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression,
Morales-Betanzos CA; Lee H; Gonzalez Ericsson PI; Balko JM; Johnson DB; Zimmerman LJ; Liebler DC
Mol Cell Proteomics; 2017 Oct; 16(10):1705-1717. PubMed ID: 28546465
[TBL] [Abstract][Full Text] [Related]
3. Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues.
Zhang Q; Salzler R; Dore A; Yang J; Ma D; Olson WC; Liu Y
J Proteome Res; 2018 Nov; 17(11):3932-3940. PubMed ID: 30277784
[TBL] [Abstract][Full Text] [Related]
4. Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer.
Kowalski A; Malinowska K; Olszewski J; Zielińska-Bliźniewska H
Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356594
[TBL] [Abstract][Full Text] [Related]
5. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
[TBL] [Abstract][Full Text] [Related]
6. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
[TBL] [Abstract][Full Text] [Related]
7. [Progress in PD-1/PD-L1, PD-L2 signaling pathway and its role in host anti-tuberculosis immunity].
Yu XW; Zhang JA; Xie JP
Zhonghua Jie He He Hu Xi Za Zhi; 2024 May; 47(5):485-489. PubMed ID: 38706074
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice.
Yassin M; Sadowska Z; Djurhuus D; Nielsen B; Tougaard P; Olsen J; Pedersen AE
Immunology; 2019 Sep; 158(1):35-46. PubMed ID: 31429085
[TBL] [Abstract][Full Text] [Related]
9. Molecular cloning, expression and characterization of Pekin duck programmed death-1.
Yao Q; Fischer KP; Tyrrell DL; Gutfreund KS
Gene; 2019 Jun; 702():182-193. PubMed ID: 30910561
[TBL] [Abstract][Full Text] [Related]
10. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
[TBL] [Abstract][Full Text] [Related]
12. Structure and interactions of the human programmed cell death 1 receptor.
Cheng X; Veverka V; Radhakrishnan A; Waters LC; Muskett FW; Morgan SH; Huo J; Yu C; Evans EJ; Leslie AJ; Griffiths M; Stubberfield C; Griffin R; Henry AJ; Jansson A; Ladbury JE; Ikemizu S; Carr MD; Davis SJ
J Biol Chem; 2013 Apr; 288(17):11771-85. PubMed ID: 23417675
[TBL] [Abstract][Full Text] [Related]
13. Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach.
Khedri M; Abnous K; Rafatpanah H; Nabavinia MS; Taghdisi SM; Ramezani M
Immunol Invest; 2020 Jul; 49(5):535-554. PubMed ID: 32429721
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PD1:PD-L1 interaction by an E. coli-derived optimized PD1 variant.
Brand Shwartz M; Assor M; Dotan N; Ratzon E; Cohen E; Ruimi N; Bloch I; Gal M; Yadid I
Biochem Biophys Res Commun; 2018 Nov; 506(3):731-738. PubMed ID: 30384998
[TBL] [Abstract][Full Text] [Related]
15. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.
Hatam LJ; Devoti JA; Rosenthal DW; Lam F; Abramson AL; Steinberg BM; Bonagura VR
Clin Cancer Res; 2012 Apr; 18(7):1925-35. PubMed ID: 22322668
[TBL] [Abstract][Full Text] [Related]
16. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
[TBL] [Abstract][Full Text] [Related]
17. Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours.
Pinato DJ; Vallipuram A; Evans JS; Wong C; Zhang H; Brown M; Dina RE; Trivedi P; Akarca AU; Marafioti T; Mauri FA; Sharma R
Neuroendocrinology; 2021; 111(5):465-474. PubMed ID: 32097935
[TBL] [Abstract][Full Text] [Related]
18. The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals.
Philips EA; Garcia-España A; Tocheva AS; Ahearn IM; Adam KR; Pan R; Mor A; Kong XP
J Biol Chem; 2020 Apr; 295(14):4372-4380. PubMed ID: 31882544
[TBL] [Abstract][Full Text] [Related]
19. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
20. Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.
Kinch A; Sundström C; Baecklund E; Backlin C; Molin D; Enblad G
Leuk Lymphoma; 2019 Feb; 60(2):376-384. PubMed ID: 30033844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
